A number of other equities analysts have also recently commented on QTNT. ValuEngine downgraded shares of Intersect ENT from a buy rating to a hold rating in a research report on Monday, June 3rd. Jefferies Financial Group reiterated a hold rating on shares of Revlon in a research report on Tuesday, March 5th. Finally, Zacks Investment Research cut shares of Haynes International from a hold rating to a sell rating in a research note on Wednesday, May 8th.
QTNT stock traded up $0.10 during trading hours on Wednesday, reaching $10.62. 448,456 shares of the stock were exchanged, compared to its average volume of 360,032. The company has a market cap of $692.90 million, a P/E ratio of -5.41 and a beta of 0.88. The firm’s 50-day simple moving average is $9.34. The company has a debt-to-equity ratio of 72.27, a quick ratio of 3.98 and a current ratio of 4.59. Quotient has a 12 month low of $5.52 and a 12 month high of $11.15.
In related news, President Edward Farrell sold 22,500 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $8.67, for a total transaction of $195,075.00. Following the transaction, the president now owns 2,133 shares of the company’s stock, valued at approximately $18,493.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Jeremy Stackawitz sold 21,495 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $9.93, for a total transaction of $213,445.35. Following the completion of the transaction, the president now directly owns 131,939 shares in the company, valued at approximately $1,310,154.27. The disclosure for this sale can be found here. 17.40% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the business. SlateStone Wealth LLC purchased a new position in shares of Quotient in the 4th quarter valued at approximately $91,000. Niemann Capital Management Inc. acquired a new stake in shares of Quotient during the 1st quarter worth approximately $101,000. Resources Investment Advisors Inc. acquired a new stake in Quotient in the 1st quarter valued at $105,000. Rehmann Capital Advisory Group acquired a new stake in Quotient during the 1st quarter worth $154,000. Finally, Westfield Capital Management Co. LP acquired a new stake in Quotient during the 1st quarter worth $217,000. Institutional investors own 63.91% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Article: Blockchain
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.